Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?-Reference-Cited by-同舟云学术

Sodium-Glucose Cotransporter 2 Inhibitors Decrease the Risk of Acute, Severe Illness: Has the Time Come to Administer Them in the Acute Setting?

Published:2023-08-17 Issue:9 Volume:51 Page:e185-e186
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:

Author:

Patoulias Dimitrios¹²

Affiliation:

1. Second Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece.

2. Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration,” Thessaloniki, Greece.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference5 articles.

1. Risk of ICU admission and related mortality in patients with sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors: A territory-wide retrospective cohort study.;Ng;Crit Care Med,2023

2. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.;Wu;Diabetes Metab,2022

3. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial.;Voors;Nat Med,2022

4. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial.;Kosiborod;Lancet Diabetes Endocrinol,2021

5. Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: Clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.;Mazer;Curr Opin Cardiol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The authors reply;Critical Care Medicine;2023-08-17